DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020786/S-035
NDA 021704/S-018

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC
Attention: Doris Sincak, MS
Manager
55 Corporate Drive
Bridgewater NJ 08807

Dear Ms. Sincak:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received December 4, 2015, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA NUMBER:	20786	21704
SUPPLEMENT NUMBER:	35	18
PRODUCT NAME:	Allegra-D 12 Hour Allergy and Congestion (fexofenadine hydrochloride 60 mg and pseudoephedrine hydrochloride 120 mg) extended release tablets	Allegra-D 24 Hour Allergy and Congestion (fexofenadine hydrochloride 180 mg and pseudoephedrine hydrochloride 240 mg) extended release tablets

These "Prior Approval" supplements provide for revised labeling to update the shelf presence including changes to colors, graphics and fonts, and modifications, deletions and repositioning of text.

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling for ALLEGRA-D® ALLERGY & CONGESTION and must be in the "Drug Facts" format (21 CFR 201.66), where applicable for the following SKUs:

Submitted Labeling	Submission Date	Represented Labeling
NDA 020786/S-035		
30-count outer container (carton)	12/04/2015, amended 01/14/2016	20-count and 10-count outer container
10-count immediate container (blister)	05/06/2016	N/A
NDA 021704/S-018		
15-count outer container (carton)	12/04/2015, amended 01/14/2016	10-count and 5-count outer container
5-count immediate container (blister)	05/06/2016	N/A

The FPL should be submitted electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)." Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 020786/S-035 or NDA 021704/S-018" as appropriate.** Approval of these submissions by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to these applications, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherry Stewart, Regulatory Project Manager, at (301) 796-9618.

Sincerely,

{See appended electronic signature page}

Theresa Michele, MD
Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES:
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

VALERIE S PRATT
06/02/2016